(UroToday.com) The TITAN randomized phase 3 study compared apalutamide to placebo in combination with androgen deprivation therapy for treatment of men with metastatic castration sensitive prostate cancer (mCSPC).1 The co-primary endpoints of the study were overall survival and radiographic progression free survival. The study schema is shown below.